<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01096082</url>
  </required_header>
  <id_info>
    <org_study_id>09-418</org_study_id>
    <secondary_id>HCPA FIPE GPPG: 09-418</secondary_id>
    <nct_id>NCT01096082</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3</brief_title>
  <official_title>Randomized Clinical Trial to Assess the Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <brief_summary>
    <textblock>
      Design: Phase II-III, double-blind, parallel, placebo controlled randomized Clinical trial&#xD;
&#xD;
      Background: Spinocerebellar ataxia type 3 (SCA-3) is an autosomal dominant adult-onset&#xD;
      neurodegenerative disorder for which there is no current treatment. Patients will invariably&#xD;
      become dependent from others and unable to walk during the disease course.&#xD;
&#xD;
      Hypothesis: Lithium Carbonate is safe and effective in treating neurological symptoms and&#xD;
      improving quality of life of patients with SCA3.&#xD;
&#xD;
      Outcomes:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Phase 2 - To assess safety and tolerability of Lithium Carbonate in patients with SCA3&#xD;
           after 6 months of follow-up&#xD;
&#xD;
        -  Phase 3 (if Phase II study shows safety of therapy) - To assess efficacy of Lithium&#xD;
           Carbonate in patients with SCA3 through the Neurological Examination Score for SCA 3&#xD;
           (NESSCA) after 12 months of follow-up .&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        1. - To assess efficacy on neurological function, ataxic, depressive and quality of life&#xD;
           scores of Lithium Carbonate in patients with SCA3 through the Scale for the Assessment&#xD;
           and Rating of Ataxia (SARA), 9-Hole Peg Board test, 8m walking time, PATA repetition&#xD;
           rate, Click Test, SCA Functional Index (SCAFI), Composite Cerebellar Functional Score&#xD;
           (CCFS), Beck Depression Inventory, Barthel Index and WHOQol after 6 and 12 months of&#xD;
           follow-up.&#xD;
&#xD;
        2. - To assess the effect of Lithium Carbonate in peripheral levels and expression of&#xD;
           treatment biomarkers (BDNF, NSE, HDAC, GSK-3Beta)&#xD;
&#xD;
      Study Duration: 12 months&#xD;
&#xD;
        -  Final analysis of phase 2 (safety study) at 6 months with continuous monitoring until&#xD;
           the end of phase 3 (efficacy study).&#xD;
&#xD;
        -  Preliminary analysis of efficacy on ataxia scales at 6 months of study and final&#xD;
           analysis of phase 3 at 12 months.&#xD;
&#xD;
      Obs: A futility analysis will be performed after 12 months of therapy if no statistically&#xD;
      significant difference between groups were found. This analysis will define if the study will&#xD;
      continue until 18 or 24 months of follow-up or will be ended at 12 months.&#xD;
&#xD;
      Location: Hospital de Clínicas de Porto Alegre&#xD;
&#xD;
      Subjects: 60 molecularly diagnosed SCA3 patients from the outpatient unit of the Medical&#xD;
      Genetics Service of Hospital de Clínicas de Porto Alegre&#xD;
&#xD;
      Intervention: Lithium Carbonate tablets of 300mg. Starting dose will be 300mg/day with drug&#xD;
      titration during 49 days or until achieving the defined target lithium serum level of 0.5 to&#xD;
      0.8 mEq/L&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 2 - Safety and tolerability of Lithium Carbonate treatment in patients with SCA3</measure>
    <time_frame>6 months</time_frame>
    <description>According to the Common toxicity criteria manual, version 2.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 3 - Efficacy of Lithium Carbonate treatment in patients with SCA3</measure>
    <time_frame>12 months</time_frame>
    <description>Application of the Neurological Examination Score for SCA 3 (NESSCA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Lithium Carbonate in patients with SCA3 on neurological function, ataxic, depressive and quality of life scores</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Scale for the Assessment and Rating of Ataxia (SARA), 9-Hole Peg Board test, 8m walking time, PATA repetition rate, Click Test, SCA Functional Index (SCAFI), Composite Cerebellar Functional Score (CCFS), Beck Depression Inventory, Barthel Index and WHOQol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Lithium Carbonate treatment in peripheral levels and expression of treatment biomarkers</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>BDNF, NSE, HDAC, GSK-3Beta</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Spinocerebellar Ataxia Type 3</condition>
  <condition>Machado Joseph Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lithium Carbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium Carbonate</intervention_name>
    <description>300 mg tablets, starting dose 300 mg/day</description>
    <arm_group_label>Lithium Carbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Similar shape, color and taste and the same number of tablets from the experimental group</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prior molecular diagnose of SCA3 with determined number of CAG expanded repeat.&#xD;
&#xD;
          -  Not restricted to wheelchair.&#xD;
&#xD;
          -  With disease duration between 2 and 10 years and more than 16 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Signs of cardiopathy, elevated levels of creatinine, transaminases, bilirubins more&#xD;
             than 1.5 times the normal upper limit at baseline.&#xD;
&#xD;
          -  History of previous lithium carbonate significant adverse reaction, or drug abuse or&#xD;
             alcoholism.&#xD;
&#xD;
          -  Disturbance of thyroid function at baseline.&#xD;
&#xD;
          -  Participation on another clinical trial less than 4 weeks before the study entrance.&#xD;
&#xD;
          -  Current use of valproic acid, memantine, neuroleptics and anticoagulants&#xD;
&#xD;
          -  If the individual (woman) did not agree in utilize a high effective contraceptive&#xD;
             method during the study period and 3 months after the study-end.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura B Jardim, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Genetics Service Hospital de Clinicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonas AM Saute, MD</last_name>
    <role>Study Director</role>
    <affiliation>Neurology Service Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Watase K, Gatchel JR, Sun Y, Emamian E, Atkinson R, Richman R, Mizusawa H, Orr HT, Shaw C, Zoghbi HY. Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med. 2007 May;4(5):e182.</citation>
    <PMID>17535104</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>March 29, 2010</study_first_submitted>
  <study_first_submitted_qc>March 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <last_update_submitted>January 29, 2013</last_update_submitted>
  <last_update_submitted_qc>January 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Clinicas de Porto Alegre</investigator_affiliation>
    <investigator_full_name>Laura Bannach Jardim</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>spinocerebellar ataxia</keyword>
  <keyword>Treatment</keyword>
  <keyword>Lithium carbonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Spinocerebellar Ataxias</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
    <mesh_term>Machado-Joseph Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

